Coherus outlines $175M annualized LOQTORZI target by 2028 as commercial expansion accelerates
Source: SeekingAlpha
2026-03-09 20:58:47 ET
More on Coherus BioSciences
- Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript
- Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114
- Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Coherus BioSciences Q4 2025 Earnings Preview
- Coherus Oncology prices stock offering to raise $50.1M
Read the full article on Seeking Alpha
For further details see:
Coherus outlines $175M annualized LOQTORZI target by 2028 as commercial expansion accelerates
Coherus BioSciences Inc.
NASDAQ: CHRS
CHRS Trading
8.52% G/L:
$1.91 Last:
963,328 Volume:
$1.82 Open:
CHRS Latest News
March 09, 2026 04:15:00 pm
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
March 02, 2026 09:30:00 am
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
February 17, 2026 04:11:28 pm
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
CHRS Stock Data
$262,894,453
111,104,635
0.81%
48
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
